---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020699"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:14:26.208483+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# 4DMT reports Q1 net loss $28.7M; cash runway into H1 2026 after $129M offering

## Summary
- Net loss $28.7M for Q1 2023 vs $26.3M in Q1 2022; R&D expenses $22.4M.
- Cash, equivalents and marketable securities $202M as of March 31, 2023; plus $129M net from May 2023 offering.
- Positive interim data from 4D-150 Phase 1/2 PRISM trial for wet AMD: 100% injection-free at 36 weeks in 3E10 cohort.
- Acquired worldwide rights to sCFH from Aevitas for 4D-175 (geographic atrophy) candidate.
- Enrollment of Phase 2 dose expansion for 4D-150 expected to complete Q3 2023; initial data H1 2024.

## SEC filing metadata
- accession: 0000950170-23-020699
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000095017023020699/0000950170-23-020699-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000095017023020699/fdmt-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020699
- JSON: https://secwatch.observer/filing/0000950170-23-020699.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020699.txt

## Key facts
- Earnings Releases
  4D Molecular Therapeutics, Inc. reported three months ended March 31, 2023 results: net income $28.7 million.
  - Period: three months ended March 31, 2023
  - Net income: $28.7 million
  - Result: reported results
  source text: Net loss was $28.7 million for the quarter ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650648/000095017023020699/0000950170-23-020699-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.